Percheron Therapeutics ( (AU:PER) ) just unveiled an update.
Percheron Therapeutics Limited announced the results of its General Meeting of shareholders, where all resolutions were decided by a poll. The meeting concluded with none of the proposed resolutions being carried, indicating significant shareholder engagement and decision-making. The Board expressed gratitude for the continued support from its shareholders, highlighting the company’s commitment to transparency and stakeholder involvement.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for rare diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in various inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy.
Average Trading Volume: 10,000
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $7.45M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com